Related Experiment Video
Updated: Oct 10, 2025

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Coronavirus Disease 2019-Associated Invasive Fungal Infection
John W Baddley1, George R Thompson2, Sharon C-A Chen3
1Department of Medicine, University of Maryland School of Medicine and Baltimore Veterans Affairs Medical Center, Baltimore, Maryland, USA.
Abstract:
Coronavirus disease 2019 (COVID-19) can become complicated by secondary invasive fungal infections (IFIs), stemming primarily from severe lung damage and immunologic deficits associated with the virus or immunomodulatory therapy. Other risk factors include poorly controlled diabetes, structural lung disease and/or other comorbidities, and fungal colonization. Opportunistic IFI following severe respiratory viral illness has been increasingly recognized, most notably with severe influenza. There have been many reports of fungal infections associated with COVID-19, initially predominated by pulmonary aspergillosis, but with recent emergence of mucormycosis, candidiasis, and endemic mycoses. These infections can be challenging to diagnose and are associated with poor outcomes. The reported incidence of IFI has varied, often related to heterogeneity in patient populations, surveillance protocols, and definitions used for classification of fungal infections. Herein, we review IFI complicating COVID-19 and address knowledge gaps related to epidemiology, diagnosis, and management of COVID-19-associated fungal infections.
Insights
Secondary invasive fungal infections (IFIs) complicate COVID-19 due to lung damage and immune deficits. This review examines the epidemiology, diagnosis, and management of these challenging fungal infections in COVID-19 patients.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pulmonology
Background:
- COVID-19 can lead to secondary invasive fungal infections (IFIs).
- Risk factors include lung damage, immune deficits, diabetes, and comorbidities.
- IFI is increasingly recognized after severe respiratory viral illnesses, similar to influenza.
Purpose of the Study:
- To review IFIs complicating COVID-19.
- To address knowledge gaps in epidemiology, diagnosis, and management.
- To highlight the challenges and poor outcomes associated with these infections.
Main Methods:
- Review of existing literature on fungal infections in COVID-19 patients.
- Analysis of reported cases and incidence variations.
- Discussion of diagnostic and management challenges.
Main Results:
- COVID-19-associated IFIs include aspergillosis, mucormycosis, candidiasis, and endemic mycoses.
- Incidence varies due to differences in patient populations, surveillance, and definitions.
- These infections present diagnostic challenges and are linked to adverse outcomes.
Conclusions:
- IFIs are a significant complication of COVID-19.
- Further research is needed to improve understanding of epidemiology, diagnosis, and management.
- Standardized approaches are crucial for better patient outcomes.
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Fungal Phylum Ascomycota
Fungal Phylum Basidiomycota
Endocarditis II: Clinical Features of Infective Endocarditis
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

